Latest

The Stack Fills In

Week of June 28 - July 4 This was a consolidation week, and we held the line on evidence rather than filling space with announcements. What is left, read from the top of the stack down, tells one coherent story. At the top, the deployments that survived scrutiny share a trait:

The Scaffolding Goes Up

Week of June 21 to 27, 2026 This was a consolidation week, not a breakthrough one, and the absence of a blockbuster is itself the signal. Nothing in this weeks announcements cleared an 8.0, and the top tier capped at 7.8. What happened instead is more structural and

Trial by Evidence

For three years, healthcare AI has been graded on a curve. A slick demo on a conference stage. A flattering pilot with a hand-picked denominator. A benchmark score on a dataset the model never has to face in a real clinic on a busy Tuesday. The pitch was always

Governance Got an Org Chart

Week of June 7-13, 2026 Federal AI oversight stopped being a proposal this week and became a permanent office, a coding system, and a defunding vote. In this newsletter we have tracked the rules "arriving" since March. Governance as scale advantage in March, the new reimbursement rules

The Autonomy Threshold

Week of May 31 to June 6, 2026 This was the week AI stopped asking permission. In the span of a few days, the question shifted from whether AI can perform clinical work to whether institutions are ready to let it act on its own. The clearest signal came from

Cleared and Proven, but Not Yet Paid

Healthcare AI Signal: Surfacing the real signals shaping AI in healthcare Week of May 24–30, 2026 This week, two of the three gates that move AI from promise to scale swung open, and the third stayed shut. The FDA cleared a wave of specialist-level diagnostic AI (noninvasive heart-

When Federal Dollars Become an AI Lever

An AI-armed regulator is now auditing health systems that mostly do not have AI-armed defense. That is this week's strategic risk. The federal direction has been telegraphed in this newsletter for weeks: HTI-1 rollback debate, AERO scoping, MACPAC pressure, FDA clearance escalation. This week the

The Federal Floor Just Moved Down. Everyone Else Is Moving Up.

This week the regulatory map redrew itself, and in opposite directions in adjacent agencies. HHS proposed rolling back AI health IT transparency requirements that have been the floor for vendor accountability since 2024. The FDA cleared the first continuous AI sepsis monitoring system with an 18% mortality reduction endpoint. MACPAC

From Pilot to Practice: The Operationalization Quarter Begins

Executive Read For operators, this week's signal is unambiguous. Ambient AI is no longer the question, workforce redesign around AI, clinical and back-office, is. Four deployment data points landed at named systems with documented achieved metrics, and they describe the new procurement reality. Abridge made nursing AI

The Regulator Just Moved the Map

This week, the regulator wrote the script. FDA opened the door on AI-monitored real-time clinical trials with named pharma collaborators. Science published peer-reviewed evidence of physician-level LLM reasoning. OpenEvidence, reportedly used by 40% of US physicians, pulled its product from the EU and UK over AI

The Carrot and the Stick Arrived Together

While many still chased ambient AI headlines, the FDA, CMS, and a half-dozen state regulators continued to write the rules that determine which AI gets paid for, which gets enforced against, and which gets pulled. Procurement committees will now have a different rubric to use. Health systems already operating

AI is On the Path to Becoming a Regulated Category.

This week the regulatory scaffolding for American healthcare AI arrived in a single five-day stretch. NCCN embedded an AI-derived risk threshold in cancer screening guidelines. FDA validated its first AI drug development tool. CMS wrote a national reimbursement pathway for a specific AI model. HSCC, IMDRF, ACCME, and

The New Rules of Healthcare AI Are Here: Reimbursement, Regulation, and Real Proof

This week the healthcare AI landscape crossed a threshold. CMS created a reimbursement code for AI-detected coronary calcium. The FDA signaled it is moving toward post-market oversight. Four states advanced therapy chatbot bans. The WISeR Medicare pilot launched AI-powered claims review. And Q1 digital health funding hit

The proof era has arrived: AI claims are now being tested like drugs, and health systems are paying attention.

This week it looks as if the era of vendor-led proof points is ending. Peer-reviewed trials, multicenter studies, and scale decisions driven by documented outcomes are replacing the pilot press release. Procurement committees now have evidence to demand. Health systems that already deployed are separating from those still